**Supplementary Table S1: Overview of sequencing methods for each cohort.**

|  |  |
| --- | --- |
| **Method** | **N (%)** |
| **nNGMcohort** |  |
| *EGFR*exons 18-21 | 113 (13.2) |
| *EGFR*exons 18, 19, 21 | 7 (0.8) |
| Targeted NGS Panel  | 734 (85.7) |
| Commercial | 65 (7.6) |
| Customized (LUN3,4,5\*) | 669 (78.1) |
| Total | 854 (99.8) |
| Missing |  2 (0.2) |
| **Clinical FUP cohort** |  |
| *EGFR*exons 18-21 | 50 (19.3) |
| *EGFR*exons 18, 19, 21 | 4 (1.6) |
| Targeted NGS Panel  | 204 (78.5) |
| Commercial | 16 (6.2) |
| Customized (LUN3,4,5\*) | 188 (72.3) |
| Total | 258 (99.3) |
| Missing | 2 (0.7) |
| **Co-mutationscohort** |  |
| Targeted NGS Panel  | 310 (99.9) |
| Commercial | 12 (3.8) |
| Customized (LUN3,4,5\*) | 298 (96.1) |
| Total  | 310 (99.9) |
| Missing | 0 |
| \*one of three NGS-Panel was used.  |